# NTLA — slm-full-cpu

## Metadata

ticker: NTLA
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: bcfd30e235f12ac1eb734fac43648498535b45ac52207ef98056297a552a65ad
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 686, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 166.46, "latency_s_total": 166.46, "parse_failure": 0, "prompt_tokens": 3136, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 500, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 146.317, "latency_s_total": 146.317, "parse_failure": 0, "prompt_tokens": 3035, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 133, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 35.196, "latency_s_total": 35.196, "parse_failure": 0, "prompt_tokens": 655, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 171, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 47.234, "latency_s_total": 47.234, "parse_failure": 0, "prompt_tokens": 649, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 150, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 44.616, "latency_s_total": 44.616, "parse_failure": 0, "prompt_tokens": 575, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 135, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 57.375, "latency_s_total": 57.375, "parse_failure": 0, "prompt_tokens": 769, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 924, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 135.413, "latency_s_total": 135.413, "parse_failure": 0, "prompt_tokens": 1562, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NTLA",
  "company_name": "Intellia Therapeutics, Inc.",
  "current_price": 12.26,
  "currency": "USD",
  "market_cap": 1717953280.0,
  "forward_pe": -4.7171445,
  "week_52_high": 28.25,
  "week_52_low": 7.95,
  "revenue": 59506000.0,
  "net_income": -399975008.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-26",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any factor or combination of factors may "
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-06",
    "summary": "Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that we file with the Securities and Exchange Commission (\u201cSEC\u201d). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can emerge from time to time, and we cannot predict the impact that any f"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for the year ended December 31, 2025, the key takeaways regarding risk factors for NTLA are as follows:

**1. Unproven Nature of Core Technology**
*   CRISPR genome editing technology has only recently been clinically validated for human therapeutic use.
*   In vivo CRISPR-based genome editing technologies are relatively new, and their therapeutic utility is largely unproven.
*   The approaches used to discover and develop novel therapeutics using CRISPR systems are unproven and may never lead to marketable products.

**2. Development and Regulatory Challenges**
*   Successful product development requires solving complex issues, including safe delivery of therapeutic agents into target cells, optimizing efficacy and specificity, and demonstrating safety, potency, and purity.
*   The company is in clinical-stage development for nexiguran ziclumeran (NTLA-2001), pending resolution of a clinical hold on the IND for the MAGNITUDE trial, and for lonvoguran ziclumeran (NTLA-2002).
*   While one CRISPR-edited ex vivo therapy has been approved in the U.S. and EU, no genome editing in vivo therapy has been approved in these or other key jurisdictions. Consequently, the potential for regulatory approval remains uncertain.
*   Regulatory agencies (such as the FDA, MHRA, and EMA) have limited or no experience with the clinical development of CRISPR-based therapeutics, particularly in vivo therapeutics, which may lead to additional testing requirements and delays.

**3. Commercialization and Adoption Risks**
*   Public perception, media coverage of safety issues, and ethical concerns regarding genome editing may negatively impact subject participation in clinical trials and physician/patient acceptance of treatments.
*   Physicians, healthcare providers, and third-party payors are often slow to adopt new technologies, particularly those requiring additional upfront costs and training.
*   There is no guarantee that progress in developing one CRISPR-based therapeutic will translate to success with other products.

**4. Operational and Clinical Trial Risks**
*   The company faces numerous potential delays and unforeseen events during preclinical and clinical trials, including:
    *   Inability to obtain regulatory authorization or reach agreements with trial sites and contract research organizations (CROs).
    *   Clinical trials failing to show safety or efficacy, or producing negative/inconclusive results.
    *   Challenges in patient enrollment, retention, and follow-up.
    *   Inadequate or non-existent animal models for certain human diseases.
    *   Non-compliance or performance failures by third-party contractors or investigators.
    *   Insufficient supply or quality of materials necessary for trials.
    *   Undesirable side effects or unexpected characteristics leading to trial suspension or termination.
    *   Higher-than-anticipated costs for preclinical studies and clinical trials.

**5. Financial Implications**
*   If the company is unable to develop viable product candidates, achieve regulatory approval, or successfully market and sell resulting products, it may never achieve profitability.
*   Future success is highly dependent on the successful development of CRISPR-based technologies, cellular delivery methods, and therapeutic applications.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Unproven Technology and Development Risks:** CRISPR genome editing technology, particularly in vivo therapies, is relatively new and its therapeutic utility is largely unproven. The approaches used to discover and develop these novel therapeutics are unproven and may never lead to marketable products. There is no assurance that the company will successfully solve issues related to safe delivery, efficacy, specificity, potency, purity, and safety.
*   **Regulatory Approval Uncertainty:** While one CRISPR-edited ex vivo therapy has been approved in the U.S. and EU, no genome editing in vivo therapy has been approved in these or other key jurisdictions. The potential to obtain approval for the company’s product candidates remains uncertain.
*   **Profitability Risks:** If the company fails to develop viable product candidates, achieve regulatory approval, or successfully market and sell products, it may never achieve profitability.
*   **Public Perception and Adoption Barriers:** Public perception, media coverage of safety or efficacy issues, and ethical concerns regarding genome editing may negatively impact clinical trial participation and the willingness of physicians and patients to accept these treatments. Physicians and healthcare providers may be slow to adopt new technologies due to complexity, risk, or the need for additional training and upfront costs.
*   **Patient Eligibility:** Certain patients may not be candidates for the therapies due to health conditions, genetic profiles, or other reasons.
*   **Legislative and Regulatory Changes:** Responses by government agencies to negative public perception or ethical concerns may result in new legislation, regulations, or medical standards that could limit the ability to develop, commercialize, or obtain regulatory approval for product candidates.
*   **Clinical Development Challenges:** Clinical development is a lengthy, expensive, and uncertain process. Preclinical and clinical testing is difficult to design and implement, can take many years, and outcomes are not always predictive of later trial success. Clinical trials can fail at any stage, and interim results do not necessarily predict final results.
*   **Manufacturing and Commercialization Hurdles:** The company must establish manufacturing capabilities, secure commercial manufacturing capacity, and invest in significant marketing efforts before generating revenue. There are challenges in obtaining regulatory authorization to conduct trials and meeting the stringent requirements for later-phase clinical trials.
*   **Unforeseen Events:** The company may experience unforeseen events during clinical trials that could delay or prevent marketing approval or commercialization.

## Pre-written sections (judge input)

### Financial Health

Intellia Therapeutics, Inc. (NTLA) currently trades at $12.26 with a market capitalization of approximately $1.72 billion. The company reported revenue of $59.5 million but incurred a net loss of nearly $400 million, resulting in a negative profit margin and a forward P/E ratio of -4.72. This significant net loss highlights the substantial cash burn typical of early-stage biotechnology firms focused on R&D. While the current valuation reflects these near-term losses, investors must weigh the high risk against the potential long-term value of its gene-editing pipeline.

### Recent Developments

Intellia Therapeutics recently filed its Annual Report on Form 10-K for the year ended December 31, 2025, highlighting significant risk factors that could materially adversely affect the company's business and financial condition. The filing underscores the high degree of risk associated with investing in the company's common stock, urging careful consideration of these uncertainties. With a current stock price of $12.26 and a substantial net loss of nearly $400 million, investors face continued volatility and financial challenges. The upcoming Quarterly Report on Form 10-Q, scheduled for August 6, 2026, will be critical for assessing whether these risks have been mitigated or exacerbated. Consequently, investors should monitor these regulatory filings closely for updates on the company's operational stability and strategic direction.

### SEC Filing Highlights
Intellia Therapeutics remains in clinical-stage development for its in vivo CRISPR candidates, specifically awaiting resolution of a clinical hold on the MAGNITUDE trial for nexiguran ziclumeran. The company faces significant regulatory uncertainty, as no in vivo genome editing therapies have yet received approval in key jurisdictions, and agencies possess limited experience with such novel modalities. Operational risks are heightened by potential delays in trial enrollment, manufacturing supply chain constraints, and the inherent challenges of validating unproven therapeutic technologies. Consequently, the firm’s future profitability is heavily dependent on successfully navigating these complex development hurdles and achieving commercial adoption of its pipeline assets.

### Risk Factors

*   **Unproven Technology and Clinical Uncertainty:** In vivo CRISPR genome editing is a novel field with largely unproven therapeutic utility; the company faces significant risks regarding safe delivery, efficacy, and specificity, with no assurance that development efforts will yield marketable products.
*   **Regulatory and Approval Hurdles:** No genome editing in vivo therapy has been approved in key jurisdictions to date, creating substantial uncertainty regarding the company’s ability to obtain necessary regulatory approvals for its product candidates.
*   **Public Perception and Adoption Barriers:** Ethical concerns, negative media coverage, and physician hesitation regarding the complexity and safety of genome editing may hinder clinical trial participation, market adoption, and commercial success.

## Audited (Exec Summary + Outlook)

### Executive Summary
Intellia Therapeutics is a clinical-stage biotechnology firm pioneering in vivo CRISPR genome editing, currently trading at $12.26 with a market capitalization of approximately $1.72 billion despite reporting a net loss of nearly $400 million. The stock is notable now due to the high-stakes regulatory uncertainty surrounding its pipeline, particularly the pending resolution of the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran. The single most important near-term variable shaping the investment outcome is the regulatory agency's decision to lift the clinical hold, which will determine whether the company can resume critical development activities.

### Outlook
The directional outlook for Intellia is cautiously constructive but heavily contingent on regulatory clarity and clinical progress. Key variables to monitor include the timeline for lifting the clinical hold on the MAGNITUDE trial, the company’s ability to manage cash burn given its substantial net losses, and the evolving regulatory landscape for in vivo genome editing. A favorable resolution to the clinical hold and positive data readouts would significantly strengthen the investment thesis by validating the platform’s viability and reducing execution risk. Conversely, prolonged regulatory delays, further setbacks in trial enrollment, or negative shifts in public perception regarding gene editing would weaken the thesis by extending the path to commercialization and increasing financial strain. Investors should remain vigilant for updates in the upcoming 10-Q filing and any new regulatory communications that signal a shift in the company’s operational stability.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "currently trading at $12.26"
LABEL: SUPPORTED
REASON: The source data explicitly lists `"current_price": 12.26`.

---

CLAIM: "market capitalization of approximately $1.72 billion"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 1717953280.0`, which rounds to approximately $1.72 billion.

---

CLAIM: "net loss of nearly $400 million"
LABEL: SUPPORTED
REASON: Source data shows `"net_income": -399975008.0`, which is approximately $400 million in net loss; "nearly $400 million" is accurate.

---

CLAIM: "pending resolution of the clinical hold on the MAGNITUDE trial for nexiguran ziclumeran"
LABEL: SUPPORTED
REASON: The SEC Filing Highlights (RAG) explicitly states "pending resolution of a clinical hold on the IND for the MAGNITUDE trial" for nexiguran ziclumeran (NTLA-2001).

---

CLAIM: "The single most important near-term variable shaping the investment outcome is the regulatory agency's decision to lift the clinical hold"
LABEL: SUPPORTED
REASON: This is a directional restatement of the clinical hold situation explicitly described in the SEC Filing Highlights; no specific quantitative figure is introduced that requires separate verification.

---

**OUTLOOK**

---

CLAIM: "the timeline for lifting the clinical hold on the MAGNITUDE trial"
LABEL: SUPPORTED
REASON: The clinical hold on the MAGNITUDE trial is explicitly documented in the RAG SEC Highlights; no specific timeline figure is asserted, only that it is a variable to monitor.

---

CLAIM: "the company's ability to manage cash burn given its substantial net losses"
LABEL: SUPPORTED
REASON: The net loss of ~$400 million is confirmed in the source data (`"net_income": -399975008.0`); no specific cash burn figure beyond the net loss is claimed.

---

CLAIM: "updates in the upcoming 10-Q filing"
LABEL: SUPPORTED
REASON: The SEC filing data confirms a 10-Q was filed (or scheduled) on `"filing_date": "2026-08-06"`, and the Recent Developments section explicitly references this upcoming 10-Q.

---

**SUMMARY OF FINDINGS**

All quantitative and forward-looking claims in the Executive Summary and Outlook are either directly supported by the source data or are directional restatements of explicitly documented facts. No figures were introduced that are absent from the source, no period labels were misapplied, and no derived figures failed recomputation. Notably, the brief contains relatively few hard quantitative claims beyond the stock price, market cap, and net loss — all three of which check out precisely against the raw source data.
